Repligen (RGEN) Cash from Investing Activities (2010 - 2026)
Repligen (RGEN) reported Cash from Investing Activities of -$4.0 million for Q1 2026, up 94.62% year-over-year from -$2.0 million in Q1 2025, and up 98.09% quarter-over-quarter from -$208.7 million in Q4 2025.
Repligen (RGEN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Repligen (RGEN) has 17 years of Cash from Investing Activities data on file, last reported at -$4.0 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$4.0 million, up 94.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$228.4 million (down 50.11% YoY), and the FY2025 annual result was -$298.5 million, down 245.52% from the prior year.
- Cash from Investing Activities improved to -$4.0 million in Q1 2026 per RGEN's latest filing, from -$208.7 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $64.8 million in Q2 2023 and troughed at -$208.7 million in Q4 2025.
- A 5-year average of -$43.8 million and a median of -$9.4 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 347.27% in 2023, then sank 786.25% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$121.3 million in 2022, then sank by 40.06% to -$169.9 million in 2023, then jumped by 61.88% to -$64.8 million in 2024, then plunged by 222.32% to -$208.7 million in 2025, then jumped by 98.09% to -$4.0 million in 2026.
- Business Quant data shows RGEN's Cash from Investing Activities at -$4.0 million in Q1 2026, -$208.7 million in Q4 2025, and -$7.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -914.50 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -96.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -58.03 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -42.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -77.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -90.00 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -131.58 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -133.00 Mn |
| 10 | Repligen | 7.41 Bn | 6.42 Bn | 108.28 Mn | -3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.99 Mn |
| Mar 31, 2026 | -3.99 Mn |
| Dec 31, 2025 | -208.74 Mn |
| Dec 31, 2025 | -208.74 Mn |
| Sep 30, 2025 | -7.78 Mn |
| Sep 30, 2025 | -7.78 Mn |
| Jun 30, 2025 | -7.84 Mn |
| Jun 30, 2025 | -7.84 Mn |
| Mar 31, 2025 | -74.11 Mn |
| Mar 31, 2025 | -74.11 Mn |
| Dec 31, 2024 | -64.76 Mn |
| Dec 31, 2024 | -64.76 Mn |
| Sep 30, 2024 | -5.86 Mn |
| Sep 30, 2024 | -5.86 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Mar 31, 2024 | -8.36 Mn |
| Mar 31, 2024 | -8.36 Mn |
| Dec 31, 2023 | -169.91 Mn |
| Dec 31, 2023 | -169.91 Mn |